DHX36 is a regulatory switch in the interferon-mediated antiviral response
Science Advances · 29.05.2026 · 12 (22)
DOI: 10.1126/sciadv.aef5520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 29.05.2026. Verfasst von Lisa Weixler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany. Hauptthemen laut MEDLINE: Immunity, Innate, DEAD-box RNA Helicases, Interferons, Yellow fever virus. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Innate immune and stress responses must be tightly regulated to prevent aberrant activation in the absence of pathogens. The RNA helicase DHX36 has been implicated in viral RNA sensing, but its role in immune regulation is not fully understood. Here, we show that DHX36 functions as a rheostat that restrains immune activation under homeostatic conditions while modulating antiviral signaling. Exposure to double-stranded RNA reduces DHX36 activity, enabling immune activation. In contrast, cells lacking DHX36 adopt a constitutively activated immune state characterized by accumulation of RNA G-quadruplex structures, protein kinase R (PKR)–dependent stress granule formation, and elevated interferon-stimulated gene expression. These cells also display enhanced responsiveness to the viral RNA sensor retinoic acid–inducible gene I (RIG-I) and more effectively suppress replication of a yellow fever virus replicon. Together, our findings position DHX36 as a key regulator of the type I interferon response, linking RNA structure surveillance to coordinated PKR- and RIG-I–dependent antiviral signaling and maintenance of immune homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.
- Department of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, 53127 Bonn, Germany.
- Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, 53127 Bonn, Germany.
- RNA Molecular Biology Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Lisa Weixler, Philipp S Simon, Stefan Juranek, Julia Mahlberg, Martin Schlee, Eva Bartok, Markus Hafner, Katrin Paeschke
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Weixler, L., Hilbig, D., Simon, P. S., Juranek, S., Mahlberg, J., Schlee, M., Bartok, E., Hafner, M., & Paeschke, K. (2026). DHX36 is a regulatory switch in the interferon-mediated antiviral response. Science Advances, 12(22). https://doi.org/10.1126/sciadv.aef5520
Vancouver
Weixler L, Hilbig D, Simon PS, Juranek S, Mahlberg J, Schlee M, et al. DHX36 is a regulatory switch in the interferon-mediated antiviral response. Science Advances. 2026;12(22). doi:10.1126/sciadv.aef5520
BibTeX
@article{Weixler2026,
author = {Weixler, Lisa and Hilbig, Daniel and Simon, Philipp S and Juranek, Stefan and Mahlberg, Julia and Schlee, Martin and Bartok, Eva and Hafner, Markus and Paeschke, Katrin},
title = {DHX36 is a regulatory switch in the interferon-mediated antiviral response},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {22},
doi = {10.1126/sciadv.aef5520}
}
EUVIMED